Xuying Huang
Overview
Explore the profile of Xuying Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiao Z, Yan R, Liu H, Huang X, Liang Z, An G, et al.
Cancer Prev Res (Phila)
. 2023 Oct;
16(12):669-679.
PMID: 37857481
Prevention Relevance: Immune checkpoint inhibitors have shown promising results in multiple tumor species. However, there is currently no clinical application to evaluate their therapeutic value in cancer preventive treatment. Prophylactic...
2.
Yan R, Huang X, Liu H, Xiao Z, Liu J, An G, et al.
Biomedicines
. 2023 May;
11(5).
PMID: 37239162
Objective: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is a first-line treatment for lung adenocarcinoma with EGFR-sensitive mutations, but acquired resistance to EGFR-TKIs remains a problem in clinical practice. The...
3.
Liu H, Yan R, Xiao Z, Huang X, Yao J, Liu J, et al.
Breast Cancer Res
. 2023 Apr;
25(1):43.
PMID: 37069669
Triple-negative breast cancer (TNBC) exhibits the poorest outcomes among breast cancer subtypes due to the high heterogeneity and a lasting scarcity of effectual treatments. Targeted therapies based on molecular subtypes...
4.
Zhang X, Zhou Z, Huang X, Li L, Li X, Li J
Transfusion
. 2023 Apr;
63(6):E34-E35.
PMID: 37052322
No abstract available.
5.
Liu Q, Liu H, Huang X, Fan X, Xiao Z, Yan R, et al.
Cancer Gene Ther
. 2022 Sep;
30(1):192-208.
PMID: 36151333
The chromatin-modifying enzyme ATAD2 confers oncogenic competence and proliferative advantage in malignances. We previously identified ATAD2 as a marker and driver of cell proliferation in ovarian cancer (OC); however, the...
6.
Yan R, Fan X, Xiao Z, Liu H, Huang X, Liu J, et al.
Cancer Lett
. 2022 Feb;
531:83-97.
PMID: 35157971
Lung adenocarcinoma is the most common form of lung cancer, accounting for 60% of non-small cell lung cancer (NSCLC) cases in Asian patients. Importantly, nearly half of these patients have...
7.
Ge Y, Liu H, Zhang Y, Liu J, Yan R, Xiao Z, et al.
Transl Oncol
. 2022 Jan;
17:101317.
PMID: 34998236
Immunotherapy has recently become a promising cancer therapy with extensive applications of immune checkpoint inhibitors (ICIs). However, pancreatic ductal adenocarcinoma (PDAC) appears to be unresponsive to immunotherapy due to the...
8.
Yao J, Duan L, Huang X, Liu J, Fan X, Xiao Z, et al.
Front Oncol
. 2021 Dec;
11:769727.
PMID: 34926275
Background: Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer and the seventh most prevalent cause of cancer-related death worldwide. Tumor microenvironment (TME) has been confirmed...
9.
Zhang X, Li X, Zhou Z, Huang X, Li L, Li J
Transfusion
. 2021 Dec;
62(2):E12-E13.
PMID: 34888890
No abstract available.
10.
Ge Y, Fan X, Huang X, Weygant N, Xiao Z, Yan R, et al.
Mol Cancer Res
. 2021 Oct;
19(12):1980-1991.
PMID: 34610960
Cancer stem cell (CSC) marker doublecortin-like kinase 1 (DCLK1) contributes greatly to the malignancy of gastrointestinal cancers, and DCLK1-targeted agents have potential therapeutic value. However, the molecular pathways regulated by...